Title: Targeting POGLUT1 to Promote Biliary Development in Mouse Models of Alagille Syndrome
Dr. Hamed Jafar-Nejad received his M.D. from Tehran University of Medical Sciences and learned molecular biology techniques at a research institute in Iran. After one year at the University of Ottawa, he moved to Baylor College of Medicine in Houston. He received his postdoctoral training in Notch signaling and Drosophila neurogenesis with Dr. Hugo Bellen. In December 2006, he started his research group, first at the University of Texas Health Science Center-Houston and later at Baylor, where they continued their studies on the role of glycosylation and deglycosylation in animal development. In recent years, the Jafar-Nejad laboratory has devoted significant effort to understanding the function of human rare disease genes in animal development. These collaborative studies have led to the identification of Poglut1 as a dominant genetic suppressor of the liver phenotypes in a mouse model for Alagille syndrome, the identification of a new form of muscular dystrophy caused by recessive mutations in POGLUT1, and the discovery of several pathways downstream of the deglycosylation enzyme N-glycanase 1 (NGLY1), mutations in which cause a multi-system developmental disorder. This work will likely provide novel insight into how glycans regulate animal development and might help establish new therapeutic approaches for these diseases.
Title: Sulfated glycosaminoglycans - Studies in diversity
Dr. Kitagawa received his Ph.D. in Biochemistry in 1991 from Kyoto University. He did his doctoral work in the laboratories of Prof. Ikuo Yamashina and Prof. Toshisuke Kawasaki on the purification and characterization of cancer-associated carbohydrate antigens by using monoclonal antibodies raised against human cancer cells. Dr. Kitagawa went on to do postdoctoral work with Dr. James C. Paulson at Cytel Corporation and Scripps Research Institute. In Dr. Paulson’s laboratory, he worked on the molecular cloning and characterization of several sialyltransferases. In 1994 he obtained an assistant professor position at the Department of Biochemistry, Kobe Pharmaceutical University, where he started to work on the structure and biosynthesis of sulfated glycosaminoglycans. He was promoted to associate professor in 2000 and full professor in 2005. He received the young scientist award of the Japanese Society of Carbohydrate Research in 1999, the PSJ (Pharmaceutical Society of Japan) award for young scientists in 2001, the young investigator award of the Japanese Biochemical Society in 2002, and the PSJ award for Divisional Scientific Promotions in 2013. He has continued to work on the functions and the control of the biosynthesis and degradation of sulfated glycosaminoglycans to clarify the causes of various disorders.
Title: Human Gut Bacteria Tailor Extracellular Vesicle Cargo for the Breakdown of Diet- and host-derived glycans
Dr. Feldman obtained his Ph.D. at the University of Buenos Aires, Argentina, under the supervision of Dr. Armando Parodi. After completing his postdoctoral training in Guy Cornelis and Markus Aebi labs in Switzerland, he joined the University of Alberta, in Edmonton, Canada, as an assistant professor. In 2015 he moved to the Department of Microbiology at the Washington University School of Medicine in St Louis, USA. The Feldman lab is interested in microbial glycobiology and bacterial pathogenesis. Dr. Feldman has pioneered the field of bacterial glycoengineering, which is a promising approach for the generation of novel bioconjugate vaccines. He has co-founded two companies (VaxAlta and Omniose) in this area. He is a world leader in studying the human pathogen Acinetobacter baumannii and the biogenesis of bacterial extracellular vesicles. Dr. Feldman is a fellow of the American Academy of Microbiology.
Title: Targeting Human Viruses with Broadly Protective Low-Sugar Vaccines
Professor Wong received his B.S. and M.S. degrees from National Taiwan University, and Ph.D. (1982) in Chemistry from MIT. He then worked at Harvard University as a postdoctoral fellow, became an assistant professor at Texas A&M University in 1983, and became a professor in 1987. He was Professor and Ernest W. Hahn Chair in Chemistry at the Scripps Research Institute (1989–2006), Director of Genomics Research Center (2003–2006), and President of Academia Sinica (2006-2016). He is currently the Scripps Family Chair Professor of Chemistry at The Scripps Research Institute with a joint appointment at Genomics Research Center, Academia Sinica.
Professor Wong receives numerous awards, including the U.S. Presidential Green Chemistry Challenge Award, the ACS Claude Hudson Award in Carbohydrate Chemistry, Creative Work in Synthetic Organic Chemistry, and the Cope Medal, the Wolf Prize in Chemistry. He is a member of Academia Sinica, the American Academy of Arts and Sciences, and the U.S. National Academy of Sciences.
His research interests are in the field of chemical biology and synthetic chemistry, including the synthesis of complex carbohydrates and glycoproteins associated with disease progression. He is the author of over 700 publications (H-index 144) and 100 patents.
Dr. Vered Padler-Karavani received her PhD in biochemistry from Tel Aviv University. She then did her postdoctoral training with Prof. Ajit Varki at The University of California, San Diego (UCSD) and subsequently established The Laboratory for Glycoimmunology at Tel Aviv University The George S. Wise Faculty of Life Sciences, Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research. Her research combines glycobiology, immunology, bio-nanotechnology, cancer research and xenotransplantation, and involves cutting edge technologies within these disciplines. She received several prestigious grants from the European Commission (Marie Curie, Health Consortium, ERC) to investigate various aspects of immunology of carbohydrates. With TRANSLINK health consortium (6 academic institutes, 5 hospitals and 3 companies from Israel, Italy, France, Spain, UK, Sweden, Canada and USA; https://cordis.europa.eu/project/id/603049), she investigated risk factors of animal-derived heart valve implants, in ~5,000 patients. Her research is currently focused on studying mechanisms of glycan immune recognition and responses in animal models and in humans, in vitro and in vivo. Particularly, the immunological basis of anti-carbohydrate antibodies and their implications on cancer and heart diseases, and on developing novel diagnostics and therapeutics for such diseases.
Title: Synthetic glycan-based vaccines to combat bacterial diseases: from concept to first-in-human data and beyond
Dr. Mulard graduated as an engineer from the ESPCI (Paris, France). She received a Ph.D. in Chemistry from the University Paris 6 (UPMC, Paris, France) and was trained in glycochemistry and glycan recognition as a postdoctoral fellow at the NIH (Bethesda, MD, USA). She joined the Organic Chemistry Unit at Institut Pasteur (Paris, France), where she set up a group on the Chemistry of Bacterial Carbohydrates. Her current research interests are in the area of peptide chemistry and carbohydrate chemistry. Her research programs deal with the development of chemical tools and bioactive compounds aimed at interfering with molecular phenomena governing infectious diseases. Interfacing Chemistry, Structural Biology, Immunochemistry, and Vaccinology, the special focus has been on investigating a chemistry-driven multidisciplinary strategy toward developing original conjugate vaccines against diarrheal diseases. Dr. Mulard’s major implication in translational sciences and technology transfer has led to the first-in-human Shigella synthetic carbohydrate-based vaccine candidate. Besides actively pursuing promising routes toward the next-generation glycoconjugate vaccines, she is interested in the development of novel therapeutic agents inspired by peptide and carbohydrate scaffolds. Her contribution was distinguished on various occasions, including the 2016 Thérèse Lebrasseur award from the Fondation de France.
Title: Regulation and Protein Selectivity of N-Glycan Branching Enzymes
Professor Yasuhiko Kizuka has been a researcher at Disease Glycomics Team, RIKEN, led by Dr. Naoyuki Taniguchi (2009-2017). He has joined Gifu University (Japan) as an Associate Professor since 2017, and is currently the Director and Professor of Integrated Glyco-Molecular Science Center, Institute for Glyco-core Research (iGCORE) at Gifu University.
Professor Kizuka’s glyco-related contributions include discovery of novel mode of catalytic action of glycosyltransferases, elucidation of glycosyltransferase structures and development of glycosyltransferase inhibitors. His Research Interests are (1) Regulation of glycosyltransferase activity; (2) Substrate protein selectivity of glycosyltransferases; (3) Physiological functions of N-glycan branches.
Title: Chemical Glycobiology Studies on Bacterial Pseudaminic Acid
Professor Xuechen Li received his Ph.D. from Harvard University in 2007. After postdoctoral work in the laboratory of Prof. Samuel Danishefsky at the Memorial Sloan Kettering Cancer Center in New York, he joined the Department of Chemistry at the University of Hong Kong as an Assistant Professor in 2009 and was promoted to Associate Professor in 2014 and Professor in 2018. He currently serves as the Associate Dean (Research & Graduate Studies) of Faculty of Science. The central theme of Professor Li’s research focuses on the chemical biology of synthetic biomolecules (proteins, carbohydrates, and glycoconjugates) to study fundamental biological questions and develop potential therapeutic applications.
Title: Cell-based Mucin Array for Discovery and Characterization of Mucinase and Glycan-Binding Modules.
Dr. Narimatsu is an Associate Professor at Copenhagen Center for Glycomics, Ph.D. (2008, Tsukuba University, Japan). His study focuses on the structure, biosynthesis, and genetic regulation of complex carbohydrates. He received training for eight years at the glycobiology lab, Research Center for Medical Glycoscience (RCMG) in Japan. Joined a Center of Excellence in Glycomics funded by the Danish National Research Foundation at the University of Copenhagen in 2012 and contributed to developing a comprehensive and high-throughput platform for CRISPR/Cas9 gene targeting of the human glycome (GlycoCRISPR), a large library of glycoengineered cells (GlycoDisplay), a cell-based platform for the display and production of human Mucin tandem repeat (MucinDisplay). His research interests include a basic understanding of genetic regulation and biosynthesis of protein glycosylation, consequences of deficiencies in glycosylation in diseases, and biomedical applications.
His group has taken a global "glycogenome" engineering approach to protein glycosylation and proposed a Cell-Based glycan array platform to display the human glycome–i.e., display of all human glycans on proteins, proteoglycans, and lipids. This self-renewable array is useful for discovering biological interactions involving glycans, and screening of true high-affinity interactions with glycans requires the natural biological context of specific proteins and cell surfaces.
The research activity of Professor De Castro is in carbohydrate structural chemistry, and her training in this subject started during her bachelor thesis, which focused on plant polysaccharides. Since then, even though Professor De Castro continued her work on carbohydrate structural chemistry, she shifted her interests and dedicated her activity to the analysis of the bacterial membrane carbohydrate components, paying attention, but not limiting the work, to Gram-negative bacteria and lipopolysaccharides (LPSs). This work has resulted in the development of state-of-the-art chemical and spectroscopical approaches that have been later applied with success to different kinds of carbohydrates, such as those from the bacteria of the gut microbiota or those from the giant viruses. This last topic is Professor De Castro's major field of research.
Professor De Castro is the author/co-author of about 130 peer-reviewed publications, an associated Editor for the journal Carbohydrate Polymers, and a member of the editorial board of Carbohydrate Research, Glycobiology, and Polysaccharides. She fruitfully collaborates with different research institutions, such as the Department of Plant Pathology (University of Nebraska Lincoln, NE, USA) and the Structural and Genomics Information Laboratory in Marseille (France).
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.